CN101235084A - Method for preparing bone morphogenic protein BMP-2 mature peptide - Google Patents
Method for preparing bone morphogenic protein BMP-2 mature peptide Download PDFInfo
- Publication number
- CN101235084A CN101235084A CNA2007100671383A CN200710067138A CN101235084A CN 101235084 A CN101235084 A CN 101235084A CN A2007100671383 A CNA2007100671383 A CN A2007100671383A CN 200710067138 A CN200710067138 A CN 200710067138A CN 101235084 A CN101235084 A CN 101235084A
- Authority
- CN
- China
- Prior art keywords
- bmp
- gene
- mature peptide
- dsba
- pet39
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 72
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 title claims abstract description 59
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 title claims abstract description 52
- 210000000988 bone and bone Anatomy 0.000 title claims description 42
- 230000000921 morphogenic effect Effects 0.000 title claims description 38
- 238000000034 method Methods 0.000 title claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 135
- 239000013612 plasmid Substances 0.000 claims abstract description 67
- 241000894006 Bacteria Species 0.000 claims abstract description 61
- 230000014509 gene expression Effects 0.000 claims abstract description 23
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 22
- 150000001413 amino acids Chemical class 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 238000000746 purification Methods 0.000 claims abstract description 14
- 108020004705 Codon Proteins 0.000 claims abstract description 12
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 60
- 108020004414 DNA Proteins 0.000 claims description 56
- 230000004927 fusion Effects 0.000 claims description 42
- 238000013467 fragmentation Methods 0.000 claims description 28
- 238000006062 fragmentation reaction Methods 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 22
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 238000000926 separation method Methods 0.000 claims description 19
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 18
- 108010013369 Enteropeptidase Proteins 0.000 claims description 16
- 241000588724 Escherichia coli Species 0.000 claims description 14
- 102100029727 Enteropeptidase Human genes 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 11
- 102000035195 Peptidases Human genes 0.000 claims description 11
- 229930182817 methionine Natural products 0.000 claims description 11
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 230000004087 circulation Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 108091081024 Start codon Proteins 0.000 claims description 7
- 238000000855 fermentation Methods 0.000 claims description 7
- 230000004151 fermentation Effects 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 6
- 150000002460 imidazoles Chemical class 0.000 claims description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- 239000013522 chelant Substances 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 230000008521 reorganization Effects 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 108010002747 Pfu DNA polymerase Proteins 0.000 claims description 3
- 238000000137 annealing Methods 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 2
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 claims description 2
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- -1 isopropylthio- Chemical class 0.000 claims description 2
- 230000001320 lysogenic effect Effects 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 238000011218 seed culture Methods 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 claims 4
- 108090000190 Thrombin Proteins 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 238000004153 renaturation Methods 0.000 abstract description 10
- 238000001042 affinity chromatography Methods 0.000 abstract description 6
- 238000005215 recombination Methods 0.000 abstract 5
- 230000006798 recombination Effects 0.000 abstract 5
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 101710167839 Morphogenetic protein Proteins 0.000 abstract 1
- 230000007910 cell fusion Effects 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 34
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 21
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 10
- 239000000178 monomer Substances 0.000 description 9
- 238000013461 design Methods 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 210000001322 periplasm Anatomy 0.000 description 6
- 239000000710 homodimer Substances 0.000 description 5
- 210000003000 inclusion body Anatomy 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 238000005267 amalgamation Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000034127 bone morphogenesis Effects 0.000 description 2
- 102220369447 c.1352G>A Human genes 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220004457 rs11567847 Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 1
- 101710106398 Disulfide bond formation protein A Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GUXQAPACZVVOKX-AVGNSLFASA-N His-Lys-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N GUXQAPACZVVOKX-AVGNSLFASA-N 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- KMWFXJCGRXBQAC-CIUDSAMLSA-N Ser-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N KMWFXJCGRXBQAC-CIUDSAMLSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102220023256 rs387907547 Human genes 0.000 description 1
- 102220023258 rs387907548 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010066925 sleep-promoting factor B Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides a preparation method of recombination bone morphogenetic protein BMP-2 mature peptide, comprising deleting the 2-18 amino acid encoding genes of DsbA gene signal peptide, keeping the codon of the first methilanin as starting codon to obtain a section recombined in expression carrier to obtain recombination plasmid 1, recombining the DNA of the bone morphogenetic protein BMP-2 complete mature peptide in the descending of the DsbA gene of recombination plasmid 1 to obtain recombination plasmid 2, transferring the recombination plasmid 2 into the thallus of expression host strain to obtain engineering bacteria, via cultivation and adding inducer to express target gene, breaking bacteria, separating and purifying to obtain DsbA-BMP-2 fusion protein, cutting the DsbA-BMP-2 fusion protein via prolease, separating to obtain the one morphogenetic protein BMP-2 mature peptide. The inventive product has same amino acid sequence of natural BMP-2 mature peptide, to realize soluble cell fusion expression, while the fusion protein can be purified further via Ni2+ affinity chromatography to simplify the purification before BMP-2 renaturation.
Description
(1) technical field
The present invention relates to prepare the method for bone morphogenic protein BMP-2-2 mature peptide, particularly obtain method with the on all four BMP-2 mature peptide of natural B MP-2 mature peptide aminoacid sequence.
(2) background technology
(Bone Morphogenetic Protein-2 BMP-2) belongs to the transforming growth factor superfamily member to bone morphogenesis protein-2.BMP has the undifferentiated mesenchymal cell of inducing to cartilage, bone differentiation, and the formation and the growth of embryo's bone and multiple organ played important regulating effect.The induced osteogenesis activity of BMP uniqueness makes it in skeletal injury and illness, as the fracture, bone is damaged and the oral cavity quite has broad application prospects in the face surgery.In recent years, by the DNA recombinant technology, the reorganization of kind more than ten bmp protein has all obtained broad research in basis and clinical application, and in organic evolution, the research of aspect effects such as growth and heredity just deepens continuously to BMP.
BMP first mode with precursor in cell produces, and comprises the mature peptide of signal peptide, propetide and carboxyl terminal.The halfcystine that contains 7 high conservatives in the mature peptide, they form three intrachain disulfide bonds and interchain disulfide bond and two polypeptide chains are connected to dimer, the BMP precursor protein is through N position glycosylation, proteolytic enzyme cleaves and Dimerized and form the BMP mature peptide, its active formation mostly is its homodimer, does not have glycosylated homodimer still to have biologic activity.Multiple histocyte is in the different steps expressed BMP of fetal development, and isolated BMP from multiple animal bone tissues such as ox, mouse, rabbit, people.In addition, all contain abundant BMP in the tissues such as dentine, placenta, osteosarcoma.The application of radiation immunological technique can detect the BMP in the serum, and the about 14-18n/mlg of grownup, children are 20-72ng/ml.
First amino acid of natural B MP-2 mature peptide is not methionine(Met), conventional technology of preparing is the N-terminal interpolation methionine(Met) at mature peptide or truncation type, utilize intestinal bacteria directly to express, the inclusion body renaturation method prepares BMP-2, rhBMP-2 as East China gene engineering institute exploitation truncation type, after removing 7 amino acid of N end, methionine(Met) of artificial interpolation, with its codon ATG as initiator codon, efficiently express in Escherichia coli cell, the inclusion body protein renaturation has obtained the biological activity homodimer.
Before the present invention, " preparation of human bone morphogenesis protein-2 eukaryon expression plasmid, transfection and expression " that modern medicine 33 volume 5 phases (2005/10) Kang Chunyu Zhang Qingguo deliver introduced the method for preparing the total length eukaryon expression plasmid pcDNA3.1-BMP2 that carries hBMP-2, by liposome method with the transfection of resulting reorganization eucaryon plasmid in the rabbit bone marrow stroma cell, carry out gradient screening with G418, thus obtain can stably express hBMP-2 cell clone.Adopt RT-polymerase chain reaction (RT-PCR) to detect the expression of marrow stromal cell (MSCs) hBMP-2mRNA.
Chinese patent application CN1484651 has introduced protein has been expressed in prokaryotic organism, this is made up of a kind of proteinic presequence or its part of TGF-beta superfamily by the marking protein amino terminal, protein or the proteinic ripe zone of another kind of TGF-beta superfamily are connected on this protein, and the protein that is connected has the homology with maturation zone BMP-2 at least 35%.Protein expression is having at least a part of protein to obtain with the form of inclusion body.
As everyone knows, it is with low cost to utilize protokaryon system expression pharmaceutical protein to have, and is easy to the advantage of scale operation.Because deglycosylated BMP-2 still has biologic activity, this has created condition for protokaryon system expressed BMP-2, the recombinant human B MP-2 that gene engineering institute in East China successfully utilizes intestinal bacteria to prepare to have biologic activity.But product that obtains and natural BMP-2 aminoacid sequence are inconsistent, are used for human body and may produce immunogenicity.Have the low advantage of cost though utilize inclusion body to prepare target protein, contain certain foreign protein and nucleic acid in the inclusion body, target protein accounts for about 80% of total protein.
(3) summary of the invention
The invention provides a kind of method for preparing bone morphogenic protein BMP-2-2 mature peptide, the product that this method makes can be in full accord with natural B MP-2 mature peptide aminoacid sequence, for realizing purpose of the present invention, the present invention adopts following technical scheme, and the method that the present invention prepares the BMP-2 mature peptide comprises following sequential steps:
(1) the 2nd～18 amino acid encoding gene of deletion DsbA gene signal peptide, the codon that keeps first methionine(Met) is as initiator codon, obtain the encoding dna fragmentation of the DsbA that do not contain signal peptide is reconstituted in this fragment in the expression vector, obtains recombinant plasmid 1; Described DsbA gene can escherichia coli chromosome DNA come out as template amplification, also the plasmid that contains the DsbA gene such as available pET comes out as template amplification, it is easier to do template with plasmid.Also can manually obtain purpose DsbA gene theoretically with the method for chemosynthesis.
(2) will the encode DNA of the complete mature peptide of bone morphogenic protein BMP-2-2 is reconstituted in the downstream of DsbA gene in the recombinant plasmid 1, obtains recombinant plasmid 2;
(3) recombinant plasmid 2 is transformed in the thalline of host strain, obtains engineering bacteria, described host bacterium is the DE3 lysogenic bacteria of the escherichia coli host of no thioredoxin reductase defective;
(4) engineering bacteria is cultivated in containing antibiotic substratum, adds inductor and makes destination gene expression;
(5) the engineering bacteria cell is through broken bacterium, and separation and purification obtains the BMP-2 fusion rotein;
The proteolytic enzyme enzyme is cut the BMP-2 fusion rotein, obtains described bone morphogenic protein BMP-2-2 mature peptide through separation.
Wherein, the plasmid that contains the DsbA gene in the described step (1) is preferably pET39.Also contain this gene among the bacillus coli gene group DNA, can obtain the gene of encoding D sbA with the PCR method amplification.Host strain is preferably e. coli bl21 (DE3) in the described step (3).Being expressed under the shortage oxidation envrionment conditions of goal gene carried out in the described step (4).Proteolytic enzyme is enteropeptidase or recombinant enterokinase light chain in the described step (6).
The preparation method of described bone morphogenic protein BMP-2-2 mature peptide, in the described step (2), between the DNA of the complete mature peptide of bone morphogenic protein BMP-2 in the recombinant plasmid 2-2 and the downstream of DsbA gene, also reorganization has the sequence of coding " Linker-6His-proteolytic enzyme recognition site ".Described 6His parts also can be positioned at the upstream of DsbA gene, and the proteolytic enzyme recognition site is an enteropeptidase.Specifically, for example, get the plasmid pET39 that contains the DsbA gene, the DsbA signal peptide gene among the deletion pET39 obtains recombinant plasmid 1:pET39 (SP-); To the encode DNA splicing of dna fragmentation with coding bone morphogenic protein BMP-2-2 mature peptide of " Linker-6His-Eksite " obtains the dna fragmentation of coding " Linker-6His-Eksite-BMP-2 "; The dna fragmentation of " Linker-6His-Eksite-BMP-2 " will encode again by the downstream that restriction enzyme BspTI and BamHI are reconstituted in DsbA gene among the recombinant plasmid 1:pET39 (SP-), obtain recombinant plasmid 2:pET39 (SP-BMP-2).
Described method recommends in the following order step to carry out:
(1) with the plasmid pET39 that contains the DsbA gene as pcr template, utilize the 2nd～18 the amino acid encoding gene of DsbA signal peptide gene among the round pcr deletion pET39, the codon that keeps first methionine(Met) is as initiator codon, the dna fragmentation that obtains is reconstituted in the expression vector, obtains recombinant plasmid 1:pET39 (SP-);
(2) DNA of the complete mature peptide of bone morphogenic protein BMP-2-2 is reconstituted in the downstream of DsbA gene in the recombinant plasmid 1, obtains recombinant plasmid 2:pET39 (SP-BMP-2);
(3) recombinant plasmid 2:pET39 (SP-BMP-2) is transformed in the colibacillary thalline of host strain, obtains engineering bacteria;
(4) engineering bacteria is cultivated in the Luria-Bertani substratum, makes Target Fusion albumen obtain expressing;
(5) the engineering bacteria cell is through broken bacterium, and separation and purification obtains the BMP-2 fusion rotein;
(6) cut the BMP-2 fusion rotein with the enteropeptidase enzyme, obtain described bone morphogenic protein BMP-2-2 mature peptide through separation.
Further, the preparation method of bone morphogenic protein BMP-2-2 mature peptide, preferably step is carried out in the following order:
(1) be template with the plasmid pET39 that contains the DsbA gene, delete the 2nd～18 the amino acid encoding gene of DsbA signal peptide gene in this plasmid, the codon that keeps first methionine(Met) is as initiator codon, the fragment that obtains is reconstituted in the expression vector, obtains recombinant plasmid 1:pET39 (SP-);
(2) will the encode DNA splicing of dna fragmentation with coding bone morphogenic protein BMP-2-2 mature peptide of " Linker-6His-Eksite " obtains the dna fragmentation of coding " Linker-6His-Eksite-BMP-2 "; The dna fragmentation of " Linker-6His-Eksite-BMP-2 " of will encoding again is reconstituted in the downstream of DsbA gene among the recombinant plasmid 1:pET39 (SP-), obtains recombinant plasmid 2:pET39 (SP-BMP-2);
(3) recombinant plasmid 2:pET39 (SP-BMP-2) is transformed in the thalline of host strain E.coli BL21 (DE3), obtains engineering bacteria;
(4) engineering bacteria is in the Luria-Bertani substratum, and 30 ℃, 200r/min are cultivated OD
600About 0.5 o'clock, adding final concentration was 0.1～1mM inductor isopropylthio-, and 30～37 ℃ are continued to cultivate 2～10h down, make destination gene expression;
(5) after the fermentation ends, centrifugal collection engineering bacteria cell, centrifugal behind the broken bacterium, the collection supernatant liquor is crossed and is contained Ni
2+Chelate column, with the pre-wash-out of 50mM imidazole buffer, containing the buffer solution elution target protein of imidazoles 120～150mM, collect elutriant; 50mM imidazole buffer (pH7.3) preparation: get imidazoles 0.68g and sodium-chlor 1.17g, add water and make and be dissolved into 100ml, add 0.1mol/ml hydrochloric acid soln 42.2ml, thin up is to 200ml, promptly again.
(6) in the elutriant that contains the BMP-2 fusion rotein, add the diethylamine tetraacethyl of final concentration 0.1～1mM, and enteropeptidase 5U/mL, carry out enzyme under 25 ℃ to cut, the proteolytic enzyme enzyme is cut fusion rotein, obtains described bone morphogenic protein BMP-2-2 mature peptide through separation.U is the enzyme unit that lives, and is defined as under 23 ℃ of conditions, 50 μ g trypsinogens 95% is converted into the required enzyme amount of trypsinase in 8 hours, down with.
Further again, specifically, the preparation method of bone morphogenic protein BMP-2-2 mature peptide step in the following order carries out:
(1) be masterplate with the plasmid pET39 that contains the DsbA gene,
Primer: DsbA-1:5 '-AAGCATATGGCGCAGTATGAAGAT-3 ',
DsbA-2：5’-TCGCTTAAGTATTTCACTGT-3’，
PCR parameter: 94 ℃ of 3min
3 circulations of 72 ℃ of 1min of 40 ℃ of 30s of 94 ℃ of 30s
27 circulations of 72 ℃ of 1min of 48 ℃ of 30s of 94 ℃ of 30s
72℃?10min
4℃ 10min
Cut PCR product and pET39 plasmid with NdeI and BspTI enzyme, make original DsbA gene among the dna fragmentation displacement pET39 that does not contain signal peptide gene, obtain not contain the recombinant plasmid 1:pET39 (SP-) of DsbA signal peptide gene;
(2) will the encode dna fragmentation of " Linker-6His-Eksite ":
ATA
CTTAAGCGAGAAAAAAGGTTCTGGTTCTGGTCATCATCATCATCATCATGATGACGATGACA AA, wherein
CTTAAGBe the BspTI recognition sequence,, obtain the dna fragmentation of coding " Linker-6His-Eksite-BMP-2 " with the DNA splicing of coding bone morphogenic protein BMP-2-2 mature peptide:
Primer Linker-1:5 '-ATA
CTTAAGCGAGAAAAAAGGTTCTGGTTCTGGTCATCATCATCAT-3 '
Primer Linker-2:5 '-TTGCTTATGCTTTGCTTGTTTGTCATCGTCATCATGATGATGATGATGATGACC 3 '
Primer BMP2-1:5 '-GACGATGACAAA
CAAGCAAAGCATAAGCAA-3 '
Primer BMP2-2:5 '-TTCGGATCCTTAGCGACAGCCACAACCTT-3 '
Getting concentration is primer Linker-1 and each 2uL of Link-2 of 10uM, adds 2uL dNTP, and 5uL10 * DNA Polymerase Buffer mends ddH
2O to 50uL reaction system, boiling water bath 10min puts into 50 ℃ of water-bath cooling 3min, adds 2.5U Pfu DNA polymerase, changes 72 water-bath 10min over to, makes two primers template each other, forms the dna double chain, obtains reaction product A;
As forward and reverse primer, is that template carry out pcr amplification with the BMP-2 gene with primer BMP2-1 and BMP2-2, and annealing temperature is made as 50 ℃, extends time 30s, obtains reaction product B;
As pcr template, carry out gene splicing with primer Linker-1 and BMP2-2 as forward and reverse primer with product A and product B, obtain the dna fragmentation of coding " Linker-6His-Eksite-BMP-2 ", reaction system and reaction parameter are as follows:
PCR parameter: 94 ℃ of 3min
30 circulations of 72 ℃ of 1min of 60 ℃ of 30s of 94 ℃ of 30s
72℃?10min
4℃ 10min；
(3) will the encode dna fragmentation of " Linker-6His-Eksite-BMP-2 " is reconstituted in the downstream of DsbA gene among the recombinant plasmid pET39 (SP-), obtains recombinant plasmid 2:pET39 (SP-BMP-2);
(4) recombinant plasmid 2:pET39 (SP-BMP-2) is transformed in the thalline of host strain E.coli BL21 (DE3), obtains engineering bacteria;
(5) engineering bacteria gets engineering bacteria seed liquid through seed culture in the Luria-Bertani substratum, cultured engineering bacteria seed liquid is inoculated into by 1% inoculum size that to shake bottled liquid measure be 20% Luria-Bertani substratum fermentation culture, and 30 ℃, 200r/min are cultivated OD
600Be about at 0.5 o'clock adding inductor isopropylthio-to final concentration is 0.2mM, continues under 30 ℃ of temperature to cultivate 3h, makes destination gene expression;
(6) after the fermentation ends, centrifugal collection engineering bacteria cell, centrifugal after the carrying out ultrasonic bacteria breaking, the collection supernatant liquor is crossed and is contained Ni
2+Chelate column, with the pre-wash-out of 50mM imidazole buffer,, collect elutriant with Tris-HCl (pH7.8) buffer solution elution that contains the 150mM imidazoles;
(7) in the elutriant that contains the BMP-2 fusion rotein, add the diethylamine tetraacethyl of final concentration 1mM, and enteropeptidase 5U/mL, carry out enzyme under 25 ℃ to cut, the proteolytic enzyme enzyme is cut fusion rotein,
Obtain described bone morphogenic protein BMP-2-2 mature peptide through separation.
The present invention at first will be the removal of DsbA signal peptide gene, to express in the born of the same parents that realize DsbA, disulfide linkage forms albumin A (disulfide bond formation protein A, DsbA) be a kind of disulfide bond isomerase that the auxiliary multiple protein that contains disulfide linkage correctly folds and has biologic activity in the colibacillus periplasm cell. found by Bardwell in 1991, be first found protein in this family, it is present in the E.coli periplasmic space (periplasm), has the strongest oxidisability, molecular weight is that 21kD.DsbA can form disulfide linkage by the interior protein of catalysis periplasmic space, and has good solvability.Natural DsbA gene contains signal peptide gene, instructs the DsbA secretion to the periplasmic space with well-oxygenated environment.The BMP-2 fusion rotein that contains seven cysteine residues forms polymer in the periplasmic space expression meeting with well-oxygenated environment by disulfide linkage.For the DsbA fusion rotein is expressed in the born of the same parents that lack well-oxygenated environment, must delete the dna fragmentation of its coded signal peptide 2-18 amino-acid residue, keep first amino acids methionine codon ATG as its beginning codon of translation.
Design 5 ' mutant primer, with the pET39 that carries the DsbA gene is template, utilize the round pcr amplification not contained the dna fragmentation of the encoding D sbA of signal peptide gene, DNA is reconstituted among the pET39 after utilizing restriction enzyme NdeI and BspTI to suddenly change, the engineering bacteria that obtains plasmid pET39 (SP-) structure coding " DsbA-Linker-6His Eksite-BMP-2 " fusion rotein is spatially separate for two major portions that make fusion rotein, designs GSGSG as connection peptides (G, S are respectively the single-letter abbreviations of glycine, Serine) at the C of DsbA end.The separation and purification of fusion rotein for convenience is in the C of Linker end design 6His affinity tag, for expression product can be used Ni
2+The affinity chromatography separation and purification creates conditions.In order to obtain and the on all four product of natural B MP-2 aminoacid sequence, at the recognition site (DDDDK) (D, K are respectively the single-letter abbreviations of aspartic acid, Methionin) of the N of BMP-2 end design enteropeptidase.Because the laboratory has had the gene of encoding BMP-2, in order to make up this project bacterium, on the basis of deleting the DsbA signal peptide gene, the BspTI site that utilizes DsbA gene 3 ' end to contain, the DNA of design coding " Linker-6His-Eksite " and the gene splicing of encoding BMP-2, DNA is reconstituted in pET39 (among the SP (-) to utilize restriction enzyme BspTI and BamHI will suddenly change afterwards.Recombinant plasmid transformed expressive host E.coli BL21 (DE3) obtains engineering bacteria.
The expression of engineering bacteria and the separation and purification of expression product, engineering bacteria grows to OD in containing antibiotic LB substratum
600About=0.5, adding final concentration is the IPTG of 0.1～1mM, makes destination gene expression, and 12000rpm after carrying out ultrasonic bacteria breaking is centrifugal for the engineering bacteria cell, utilizes SDS-PAGE to analyze precipitation and supernatant, determines the solvability of fusion rotein.
Soluble fusion rotein is through Ni
2+Affinity chromatography one step separation and purification can obtain purity greater than 95% BMP-2 fusion rotein.
The monomeric acquisition of BMP-2 mature peptide, cut fusion rotein with the recombinant enterokinase enzyme, because the solubleness of BMP-2 mature peptide in the aqueous solution is very little, cut at enzyme and to occur deposited phenomenon in the process, after the centrifugation, DsbA carrier and enteropeptidase are in supernatant liquor, and most of BMP-2 mature peptide monomer is in precipitation, thereby successfully obtain BMP-2 mature peptide monomer, BMP-2 mature peptide monomer can be used for the dimer that the renaturation method preparation has biologic activity.
Utilize the inventive method, can obtain and the on all four BMP-2 mature peptide of natural B MP-2 aminoacid sequence.And adopt after the amalgamation and expression strategy, the fusion rotein solvability is good, contains the label of affinity chromatography, can use Ni
2+The method separation and purification fusion rotein of affinity purification, purity can reach more than 95%.Enzyme is cut back BMP-2 mature peptide monomer and is precipitated out owing to the solubleness in the aqueous solution is little, can be with simple centrifugation target protein and fusion partner (DsbA carrier albumen).
The present invention compared with prior art, its beneficial effect is embodied in: in full accord with product and natural B MP-2 mature peptide aminoacid sequence that the inventive method makes; Amalgamation and expression is realized solubility expression, and fusion rotein can be used Ni
2+The affinity chromatography single step purification has further been simplified the preceding purification step of BMP-2 renaturation.
(4) description of drawings
Fig. 1 is the plasmid map of recombinant plasmid pETDsbA-BMP.
(5) embodiment:
Below with specific embodiment technical scheme of the present invention is described, but protection scope of the present invention is not limited thereto:
The removal of embodiment 1:DsbA signal peptide gene
Design of primers: DsbA-1:5 ' AAGCATATGGCGCAGTATGAAGAT 3 ' 24bp
DsbA-2：5’TCGCTTAAGTATTTCACTGT 3’20bp
Pcr template: pET39 plasmid
PCR parameter: 94 ℃ of 3min
3 circulations of 72 ℃ of 1min of 40 ℃ of 30s of 94 ℃ of 30s
27 circulations of 72 ℃ of 1min of 48 ℃ of 30s of 94 ℃ of 30s
72℃?10min
4℃ 10min
Cut PCR product and pET39 plasmid with NdeI and BspTI enzyme, make original DsbA gene among the dna fragmentation displacement pET39 that does not contain signal peptide gene, the recombinant plasmid called after pET39 (SP-) of acquisition.
Embodiment 2: the acquisition of coding " Linker-6His-Eksite-BMP-2 " gene
At first according to the dna fragmentation of intestinal bacteria preference codon design coding " Linker-6His-Eksite ", sequence is as follows: ATA
CTTAAGCGAGAAAAAAGGTTCTGGTTCTGGTCATCATCATCATCATCATGATGACGATGACA AA, wherein line part is the BspTI recognition sequence.For this dna fragmentation and BMP-2 gene are spliced smoothly, design following four primers, splice with the SOE technology.
Primer Linker-1:
5’ATA
CTTAAGCGAGAAAAAAGGTTCTGGTTCTGGTCATCATCATCAT?3’46bp
Primer Linker-2:
5’TTGCTTATGCTTTGCTTGTTTGTCATCGTCATCATGATGATGATGATGATGACC?3’54bp
Primer BMP2-1:
5’GACGATGACAAA
CAAGCAAAGCATAAGCAA?3’?30bp
Primer BMP2-2:
5’TTCGGATCCTTAGCGACAGCCACAACCTT 3’?30bp
Working method:
Because primer Linker-1 and primer Linker-2 have the 18bp reverse complemental, getting concentration is primer Linker-1 and each 2uL of Link-2 of 10uM, add 2uL dNTP, 5uL 10X DNA PolymeraseBuffer mends ddH2O to 50uL reaction system, boiling water bath 10min, put into 50 ℃ of water-bath cooling 3min, add 2.5U Pfu DNA polymerase, change 72 water-bath 10min over to, make two primers template each other, form the dna double chain.Reaction product called after product A.
Again the amplification of BMP-2 gene: as forward and reverse primer, the BMP-2 gene that has obtained with the laboratory is that template is carried out pcr amplification with primer BMP2-1 and BMP2-2, and annealing temperature is made as 50 ℃, extends time 30s, the product called after product B that obtains.
Gene splicing: as pcr template, carry out gene splicing with primer Linker-1 and BMP2-2 as forward and reverse primer with product A and product B, reaction system and reaction parameter are as follows:
PCR parameter: 94 ℃ of 3min
30 circulations of 72 ℃ of 1min of 60 ℃ of 30s of 94 ℃ of 30s
72℃?10min
4℃ 10min
The PCR product called after product C that obtains is the dna fragmentation of coding " Linker-6His-Eksite-BMP-2 ".
Embodiment 3: engineering bacteria makes up
Cut product C with BspTI and BamHI enzyme, Protocols in Molecular Biology is reconstituted among the pET39 (SP-) routinely, obtain recombinant plasmid pETDsbA-BMP (plasmid map is seen Fig. 1), recombinant plasmid pETDsbA-BMP Transformed E .coli BL21 (DE3) preserves this project bacterium after order-checking is identified.Be used for expression study and production.
Embodiment 4: express test in the born of the same parents of " DsbA-Linker-6His-Eksite-BMP-2 " fusion rotein
In the 3mL LB substratum that contains the 50ug/mL kantlex, 30 ℃, 200r/min were cultivated 16 hours with single bacterium colony of aseptic toothpick picking positive colony, engineering bacteria seed liquid.
Cultured engineering bacteria seed liquid is inoculated into by 1% inoculum size that to shake bottled liquid measure be in 20% the Luria-Bertani substratum, and 30 ℃, 200r/min are cultivated OD
600About 0.5 o'clock, adding inductor IPTG was 0.2mM to final concentration, and induction exogenous gene is expressed, and continued to cultivate 3h under 30 ℃ of temperature.Collect thalline and do full bacterium SDS-PAGE analysis, can obtain the expression product that apparent molecular weight is 36kD.
Embodiment 5: the solvability analysis and the separation and purification of fusion rotein
After the fermentation ends, with the centrifugal collection engineering bacteria of 3000rpm rotating speed cell, with the resuspended thalline of 20mM Tris-HClpH8.0 damping fluid, after the carrying out ultrasonic bacteria breaking, centrifugal with centrifugal 12000rpm rotating speed, collecting precipitation and last asking are precipitated with 4M Urea respectively, the dissolving of 0.1M NaCl solution, analyze the content of precipitation and supernatant target protein with SDS-PAGE, among the present invention, fusion rotein mainly is present in the supernatant liquor, illustrates that fusion rotein is present in the engineering bacteria cell with soluble form.
(1) separation and purification of fusion rotein
Because fusion rotein contains 6His affinity purification label, fusion rotein can be adsorbed in Ni specifically
2+On the chelate column,,, collect elutriant with Tris-HCl, the pH7.8 buffer solution elution target protein that contains imidazoles 150mM with the pre-wash-out of 50mM imidazole buffer;
(2) enzyme of fusion rotein is cut and the monomeric acquisition of BMP-2 mature peptide
At Ni
2+In the elutriant that contains fusion rotein of chelating affinity chromatography, adding final concentration is the EDTA of 1mM and the enteropeptidase of 5U/mL, carrying out enzyme under 25 ℃ of conditions cuts, cut at enzyme and to discharge BMP-2 mature peptide monomer in the process, because the monomeric solvability of BMP-2 mature peptide is very little, enzyme cuts that solution gradually becomes muddy by clarification in the process.
After enzyme is cut end, with rotating speed centrifugal collecting precipitation greater than 5000rpm, with 20mM Tris-HCl washing precipitation once, be precipitated as purity greater than 90% BMP-2 mature peptide monomer, this monomer can be used for further renaturation has biologic activity with preparation reorganization homodimer.
15 determined amino acid sequence results of the monomeric N-end of BMP-2 mature peptide are N-Gln Ala Lys HisLys Gln Arg Lys Arg Leu Lys Ser Ser Cys Lys, and are in full accord with natural BMP-2 mature peptide n terminal amino acid sequence.
Embodiment 6: obtain homodimer with the external renaturation of the BMP-2 mature peptide monomer that obtains
Damping fluid dissolving BMP-2 monomer precipitation with the Tris-HCl pH8.5 that contains 8M urea, 10mM dithiothreitol (DTT) (DDT), 5mM EDTA, the room temperature lower magnetic force stirred 2 hours, with the dilution method renaturation, the final concentration of renaturation system essential substance is as follows: 0.5M L-arginine, 0.1M sodium-chlor, 0.5M urea, 1mM reduced glutathion GSH, 0.1mM Sleep-promoting factor B GSSG.Place more than 24 hours at 4-10 ℃ of refrigerator, analyze dimeric formation situation with irreducibility SDS-PAGE, along with the prolongation of renaturation time, apparent molecular weight is that the protein of 25kD increases gradually.This band disappears when analyzing with reductibility SDS-PAGE, can infer that apparent molecular weight is that the protein of 25kD is the dimer of BMP-2 mature peptide.
Embodiment 7: the gene sequencing analysis
After testing, the gene order of gained BMP-2 fusion rotein of the present invention following (the line part is a BMP-2 mature peptide gene):
ATGGCGCAGTATGAAGATGGTAAACAGTACACTACCCTGGAAAAACCGGTAGCTGGCGCGCCGCAAGTGCTGGAGTTTTTCTCTTTCTTCTGCCCGCACTGCTATCAGTTTGAAGAAGTTCTGCATATTTCTGATAATGTGAAGAAAAAACTGCCGGAAGGCGTGAAGATGACTAAATACCACGTCAACTTCATGGGTGGTGACCTGGGCAAAGATCTGACTCAGGCATGGGCTGTGGCGATGGCGCTGGGCGTGGAAGACAAAGTGACTGTTCCGCTGTTTGAAGGCGTACAGAAAACCCAGACCATTCGTTCTGCTTCTGATATCCGCGATGTATTTATCAACGCAGGTATTAAAGGTGAAGAGTACGACGCGACGTGGAACAGCTTCGTGGTGAAATCTCTGGTCGCTCAGCAGGAAAAAGCTGCAGCTGACGTGCAATTGCGTGGCGTTCCGGCGATGTTTGTTAACGGTAAATATCAGCTGAATCCGCAGGGTATGGATACCAGCAATATGTTTGTTCAGCAGTATGCTGATACAGTGAAATACTTAAGCGAGAAAAAAGGTTCTGGTTCTGGTCATCATCATCATCATCATGATGACGATGACAAA
CAAGCAAAGCATAAGCAACGGAAG AGGCTGAAATCCTCCTGCAAAAGACATCCGCTGTATGTGGATTTTAGCGA TGTGGGCTGGAACGATTGGATTGTGGCGCCGCCGGGCTATCATGCGTTTT ATTGCCATGGCGAATGCCCGTTTCCGCTGGCGGATCATCTGAACTCCACC AACCATGCGATTGTGCAGACCCTGGTGAACTCTGTGAACAGCAAAATTC CGAAAGCGTGCTGTGTGCCGACCGAACTGAGCGCGATTTCGATGCTGTA TCTGGATGAAAACGAAAAAGTGGTGCTGAAAAACTATCAGGATATGGTG GTGGAAGGTTGTGGCTGTCGCTAA；
The aminoacid sequence of gained BMP-2 fusion rotein of the present invention following (the line part is a BMP-2 mature peptide amino acid):
MAQYEDGKQYTTLEKPVAGAPQVLEFFSFFCPHCYQFEEVLHISDNVKKKLPEGVKMTKYHVNFMGGDLGKDLTQAWAVAMALGVEDKVTVPLFEGVQKTQTIRSASDIRDVFINAGIKGEEYDATWNSFVVKSLVAQQEKAAADVQLRGVPAMFVNGKYQLNPQGMDTSNMFVQQYADTVKYLSEKKGSGSGHHHHHHDDDDK
QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAF YCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLD ENEKVVLKNYQDMVVEGCGCR*；
Conclusion: in full accord with bone morphogenic protein BMP-2-2 mature peptide and natural B MP-2 mature peptide aminoacid sequence that the inventive method makes.
Sequence table .ST25
SEQUENCE?LISTING
＜110〉Zhejiang Polytechnical University
＜120〉a kind of method for preparing bone morphogenic protein BMP-2-2 mature peptide
<130>
<160>8
<170>PatentIn?version?3.2
<210>1
<211>65
<212>DNA
<213>Unknown
<220>
＜223〉artificial sequence
<400>1
atacttaagc?gagaaaaaag?gttctggttc?tggtcatcat?catcatcatc?atgatgacga 60
tgaca 65
<210>2
<211>46
<212>DNA
＜213〉artificial sequence
<400>2
atacttaagc?gagaaaaaag?gttctggttc?tggtcatcat?catcat?46
<210>3
<211>54
<212>DNA
＜213〉artificial sequence
<400>3
ttgcttatgc?tttgcttgtt?tgtcatcgtc?atcatgatga?tgatgatgat?gacc 54
<210>4
<211>30
<212>DNA
＜213〉artificial sequence
<400>4
gacgatgaca?aacaagcaaa?gcataagcaa 30
<210>5
<211>29
<212>DNA
＜213〉artificial sequence
<400>5
ttcggatcct?tagcgacagc?cacaacctt 29
<210>6
<211>957
<212>DNA
＜213〉synthetic
<400>6
atggcgcagt?atgaagatgg?taaacagtac?actaccctgg?aaaaaccggt?agctggcgcg 60
ccgcaagtgc?tggagttttt?ctctttcttc?tgcccgcact?gctatcagtt?tgaagaagtt 120
ctgcatattt?ctgataatgt?gaagaaaaaa?ctgccggaag?gcgtgaagat?gactaaatac 180
cacgtcaact?tcatgggtgg?tgacctgggc?aaagatctga?ctcaggcatg?ggctgtggcg 240
atggcgctgg?gcgtggaaga?caaagtgact?gttccgctgt?ttgaaggcgt?acagaaaacc 300
cagaccattc?gttctgcttc?tgatatccgc?gatgtattta?tcaacgcagg?tattaaaggt 360
gaagagtacg?acgcgacgtg?gaacagcttc?gtggtgaaat?ctctggtcgc?tcagcaggaa 420
aaagctgcag?ctgacgtgca?attgcgtggc?gttccggcga?tgtttgttaa?cggtaaatat 480
cagctgaatc?cgcagggtat?ggataccagc?aatatgtttg?ttcagcagta?tgctgataca 540
gtgaaatact?taagcgagaa?aaaaggttct?ggttctggtc?atcatcatca?tcatcatgat 600
gacgatgaca?aacaagcaaa?gcataagcaa?cggaagaggc?tgaaatcctc?ctgcaaaaga 660
catccgctgt?atgtggattt?tagcgatgtg?ggctggaacg?attggattgt?ggcgccgccg 720
ggctatcatg?cgttttattg?ccatggcgaa?tgcccgtttc?cgctggcgga?tcatctgaac 780
tccaccaacc?atgcgattgt?gcagaccctg?gtgaactctg?tgaacagcaa?aattccgaaa 840
gcgtgctgtg?tgccgaccga?actgagcgcg?atttcgatgc?tgtatctgga?tgaaaacgaa 900
aaagtggtgc?tgaaaaacta?tcaggatatg?gtggtggaag?gttgtggctg?tcgctaa 957
<210>7
<211>318
<212>PRT
＜213〉synthetic
<400>7
Met?Ala?Gln?Tyr?Glu?Asp?Gly?Lys?Gln?Tyr?Thr?Thr?Leu?Glu?Lys?Pro
1 5 10 15
Val?Ala?Gly?Ala?Pro?Gln?Val?Leu?Glu?Phe?Phe?Ser?Phe?Phe?Cys?Pro
20 25 30
His?Cys?Tyr?Gln?Phe?Glu?Glu?Val?Leu?His?Ile?Ser?Asp?Asn?Val?Lys
35 40 45
Lys?Lys?Leu?Pro?Glu?Gly?Val?Lys?Met?Thr?Lys?Tyr?His?Val?Asn?Phe
50 55 60
Met?Gly?Gly?Asp?Leu?Gly?Lys?Asp?Leu?Thr?Gln?Ala?Trp?Ala?Val?Ala
65 70 75 80
Met?Ala?Leu?Gly?Val?Glu?Asp?Lys?Val?Thr?Val?Pro?Leu?Phe?Glu?Gly
85 90 95
Val?Gln?Lys?Thr?Gln?Thr?Ile?Arg?Ser?Ala?Ser?Asp?Ile?Arg?Asp?Val
100 105 110
Phe?Ile?Asn?Ala?Gly?Ile?Lys?Gly?Glu?Glu?Tyr?Asp?Ala?Thr?Trp?Asn
115 120 125
Ser?Phe?Val?Val?Lys?Ser?Leu?Val?Ala?Gln?Gln?Glu?Lys?Ala?Ala?Ala
130 135 140
Asp?Val?Gln?Leu?Arg?Gly?Val?Pro?Ala?Met?Phe?Val?Asn?Gly?Lys?Tyr
145 150 155 160
Gln?Leu?Asn?Pro?Gln?Gly?Met?Asp?Thr?Ser?Asn?Met?Phe?Val?Gln?Gln
165 170 175
Tyr?Ala?Asp?Thr?Val?Lys?Tyr?Leu?Ser?Glu?Lys?Lys?Gly?Ser?Gly?Ser
180 185 190
Gly?His?His?His?His?His?His?Asp?Asp?Asp?Asp?Lys?Gln?Ala?Lys?His
195 200 205
Lys?Gln?Arg?Lys?Arg?Leu?Lys?Ser?Ser?Cys?Lys?Arg?His?Pro?Leu?Tyr
210 215 220
Val?Asp?Phe?Ser?Asp?Val?Gly?Trp?Asn?Asp?Trp?Ile?Val?Ala?Pro?Pro
225 230 235 240
Gly?Tyr?His?Ala?Phe?Tyr?Cys?His?Gly?Glu?Cys?Pro?Phe?Pro?Leu?Ala
245 250 255
Asp?His?Leu?Asn?Ser?Thr?Asn?His?Ala?Ile?Val?Gln?Thr?Leu?Val?Asn
260 265 270
Ser?Val?Asn?Ser?Lys?Ile?Pro?Lys?Ala?Cys?Cys?Val?Pro?Thr?Glu?Leu
275 280 285
Ser?Ala?Ile?Ser?Met?Leu?Tyr?Leu?Asp?Glu?Asn?Glu?Lys?Val?Val?Leu
290 295 300
Lys?Asn?Tyr?Gln?Asp?Met?Val?Val?Glu?Gly?Cys?Gly?Cys?Arg
305 310 315
<210>8
<211>15
<212>PRT
<213>Unknown
<220>
＜223〉synthetic
<400>8
Gln?Ala?Lys?His?Lys?Gln?Arg?Lys?Arg?Leu?Lys?Ser?Ser?Cys?Lys
1 5 10 15
Claims (10)
1. the preparation method of bone morphogenic protein BMP-2-2 mature peptide is characterized in that described method comprises following sequential steps:
(1) the 2nd～18 amino acid encoding gene of deletion DsbA gene signal peptide, the codon that keeps first methionine(Met) is as initiator codon, obtain the encoding dna fragmentation of the DsbA that do not contain signal peptide is reconstituted in this fragment in the expression vector, obtains recombinant plasmid 1;
(2) will the encode DNA of the complete mature peptide of bone morphogenic protein BMP-2-2 is reconstituted in the downstream of DsbA gene in the recombinant plasmid 1, obtains recombinant plasmid 2;
(3) recombinant plasmid 2 is transformed in the thalline of host strain, obtains engineering bacteria, described host bacterium is the DE3 lysogenic bacteria of the escherichia coli host of no thioredoxin reductase defective;
(4) engineering bacteria is cultivated in containing antibiotic substratum, adds inductor and makes destination gene expression;
(5) the engineering bacteria cell is through broken bacterium, and separation and purification obtains the BMP-2 fusion rotein;
(6) the proteolytic enzyme enzyme is cut the BMP-2 fusion rotein, obtains described bone morphogenic protein BMP-2-2 mature peptide through separation.
2. the preparation method of bone morphogenic protein BMP-2-2 mature peptide as claimed in claim 1 is characterized in that the DsbA gene is from plasmid pET39 described in the described step (1).
3. the preparation method of bone morphogenic protein BMP-2-2 mature peptide as claimed in claim 1 is characterized in that host strain is e. coli bl21 (DE3) in the described step (3).
4. the preparation method of bone morphogenic protein BMP-2-2 mature peptide as claimed in claim 1 is characterized in that being expressed under the shortage oxidation envrionment conditions of goal gene carried out in the described step (4).
5. the preparation method of bone morphogenic protein BMP-2-2 mature peptide as claimed in claim 1 is characterized in that in the described step (6) that proteolytic enzyme is one of following: enteropeptidase, recombinant enterokinase light chain.
6. as the preparation method of one of claim 1～5 described bone morphogenic protein BMP-2-2 mature peptide, it is characterized in that in the described step (2), between the DNA of the complete mature peptide of bone morphogenic protein BMP-2 in the recombinant plasmid 2-2 and the downstream of DsbA gene, also reorganization has the sequence of coding " Linker-6His-proteolytic enzyme recognition site ".
7. the preparation method of bone morphogenic protein BMP-2-2 mature peptide as claimed in claim 6 is characterized in that described proteolytic enzyme recognition site is enteropeptidase or thrombin.
8. the preparation method of bone morphogenic protein BMP-2-2 mature peptide as claimed in claim 1, it is characterized in that described method in the following order step carry out:
(1) with the plasmid pET39 that contains the DsbA gene as pcr template, utilize the 2nd～18 the amino acid encoding gene of DsbA signal peptide gene among the round pcr deletion pET39, the codon that keeps first methionine(Met) is as initiator codon, the dna fragmentation that obtains is reconstituted in the expression vector, obtains recombinant plasmid 1:pET39 (SP-);
(2) DNA of the complete mature peptide of bone morphogenic protein BMP-2-2 is reconstituted in the downstream of DsbA gene in the recombinant plasmid 1, obtains recombinant plasmid 2:pET39 (SP-BMP-2);
(3) recombinant plasmid 2:pET39 (SP-BMP-2) is transformed in the colibacillary thalline of host strain, obtains engineering bacteria;
(4) engineering bacteria is cultivated in the Luria-Bertani substratum, makes Target Fusion albumen obtain expressing;
(5) the engineering bacteria cell is through broken bacterium, and separation and purification obtains the BMP-2 fusion rotein;
(6) cut the BMP-2 fusion rotein with the enteropeptidase enzyme, obtain described bone morphogenic protein BMP-2-2 mature peptide through separation.
9. the preparation method of bone morphogenic protein BMP-2-2 mature peptide as claimed in claim 8, it is characterized in that described method in the following order step carry out:
(1) be template with the plasmid pET39 that contains the DsbA gene, delete the 2nd～18 the amino acid encoding gene of DsbA signal peptide gene in this plasmid, the codon that keeps first methionine(Met) is as initiator codon, the fragment that obtains is reconstituted in the expression vector, obtains recombinant plasmid 1:pET39 (SP-);
(2) will the encode DNA splicing of dna fragmentation with coding bone morphogenic protein BMP-2-2 mature peptide of " Linker-6His-Eksite " obtains the dna fragmentation of coding " Linker-6His-Eksite-BMP-2 "; The dna fragmentation of " Linker-6His-Eksite-BMP-2 " of will encoding again is reconstituted in the downstream of DsbA gene among the recombinant plasmid 1:pET39 (SP-), obtains recombinant plasmid 2:pET39 (SP-BMP-2);
(3) recombinant plasmid 2:pET39 (SP-BMP-2) is transformed in the thalline of host strain E.coli BL21 (DE3), obtains engineering bacteria;
(4) engineering bacteria is in the Luria-Bertani substratum, and 30 ℃, 200r/min are cultivated OD
600About 0.5 o'clock, adding final concentration was 0.1～1mM inductor isopropylthio-, and 30～37 ℃ are continued to cultivate 2～10h down, make destination gene expression;
(5) after the fermentation ends, centrifugal collection engineering bacteria cell, centrifugal behind the broken bacterium, the collection supernatant liquor is crossed and is contained Ni
2+Chelate column, with the pre-wash-out of 50mM imidazole buffer, containing the buffer solution elution target protein of imidazoles 120～150mM, collect elutriant;
(6) in the elutriant that contains the BMP-2 fusion rotein, add the diethylamine tetraacethyl of final concentration 0.1～1mM, and enteropeptidase 5U/mL, carry out enzyme under 25 ℃ to cut, the proteolytic enzyme enzyme is cut fusion rotein, obtains described bone morphogenic protein BMP-2-2 mature peptide through separation.
10. the preparation method of bone morphogenic protein BMP-2-2 mature peptide as claimed in claim 8, it is characterized in that described method in the following order step carry out:
(1) be masterplate with the plasmid pET39 that contains the DsbA gene,
Primer: DsbA-1:5 '-AAGCATATGGCGCAGTATGAAGAT-3 ',
DsbA-2：5’-TCGCTTAAGTATTTCACTGT-3’，
PCR parameter: 94 ℃ of 3min
3 circulations of 72 ℃ of 1min of 40 ℃ of 30s of 94 ℃ of 30s
27 circulations of 72 ℃ of 1min of 48 ℃ of 30s of 94 ℃ of 30s
72℃ 10min
4℃ 10min
Cut PCR product and pET39 plasmid with NdeI and BspTI enzyme, make original DsbA gene among the dna fragmentation displacement pET39 that does not contain signal peptide gene, obtain not contain the recombinant plasmid 1:pET39 (SP-) of DsbA signal peptide gene;
(2) the DNA fragment of " Linker-6His-Eksite ": the ATA that will encode
CTTAAGCGAGAAAAAAGGTTCTGGTTCTGGTCATCATCATCATCATCATGATGACGATGACA AA, wherein
CTTAAGBe the BspTI recognition sequence,, obtain the dna fragmentation of coding " Linker-6His-Eksite-BMP-2 " with the DNA splicing of coding bone morphogenic protein BMP-2-2 mature peptide:
Primer Linker-1:5 '-ATA
CTTAAGCGAGAAAAAAGGTTCTGGTTCT
GGTCATCATCATCAT-3’
Primer Linker-2:5 '-TTGCTTATGCTTTGCTTGTTTGTCATCGTCATC
ATGATGATGATGATGATGACC?3’
Primer BMP2-1:5 '-GACGATGACAAA
CAAGCAAAGCATAAGCAA-3 '
Primer BMP2-2:5 '-TTCGGATCCTTAGCGACAGCCACAACCTT-3 '
Getting concentration is primer Linker-1 and each 2uL of Link-2 of 10uM, adds 2uL dNTP, and 5uL 10 * DNA Polymerase Buffer mends ddH
2O to 50uL reaction system, boiling water bath 10min puts into 50 ℃ of water-bath cooling 3min, adds 2.5U Pfu DNA polymerase, changes 72 water-bath 10min over to, makes two primers template each other, forms the dna double chain, obtains reaction product A;
As forward and reverse primer, is that template carry out pcr amplification with the BMP-2 gene with primer BMP2-1 and BMP2-2, and annealing temperature is made as 50 ℃, extends time 30s, obtains reaction product B;
As pcr template, carry out gene splicing with primer Linker-1 and BMP2-2 as forward and reverse primer with product A and product B, obtain the dna fragmentation of coding " Linker-6His-Eksite-BMP-2 ", reaction system and reaction parameter are as follows:
PCR parameter: 94 ℃ of 3min
30 circulations of 72 ℃ of 1min of 60 ℃ of 30s of 94 ℃ of 30s
72℃ 10min
4℃ 10min；
(3) will the encode dna fragmentation of " Linker-6His-Eksite-BMP-2 " is reconstituted in the downstream of DsbA gene among the recombinant plasmid pET39 (SP-), obtains recombinant plasmid 2:pET39 (SP-BMP-2);
(4) recombinant plasmid 2:pET39 (SP-BMP-2) is transformed in the thalline of host strain E.coli BL21 (DE3), obtains engineering bacteria;
(5) engineering bacteria gets engineering bacteria seed liquid through seed culture in the Luria-Bertani substratum, cultured engineering bacteria seed liquid is inoculated into by 1% inoculum size that to shake bottled liquid measure be 20% Luria-Bertani substratum fermentation culture, and 30 ℃, 200r/min are cultivated OD
600Be about at 0.5 o'clock adding inductor isopropylthio-to final concentration is 0.2mM, continues under 30 ℃ of temperature to cultivate 3h, makes destination gene expression;
(6) after the fermentation ends, centrifugal collection engineering bacteria cell, centrifugal after the carrying out ultrasonic bacteria breaking, the collection supernatant liquor is crossed and is contained Ni
2+Chelate column, with the pre-wash-out of 50mM imidazole buffer,, collect elutriant with Tris-HCl, the pH7.8 buffer solution elution that contains the 150mM imidazoles;
(7) in the elutriant that contains the BMP-2 fusion rotein, add the diethylamine tetraacethyl of final concentration 1mM, and enteropeptidase 5U/mL, carry out enzyme under 25 ℃ to cut, the proteolytic enzyme enzyme is cut fusion rotein, obtains described bone morphogenic protein BMP-2-2 mature peptide through separation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100671383A CN101235084A (en) | 2007-01-31 | 2007-01-31 | Method for preparing bone morphogenic protein BMP-2 mature peptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007100671383A CN101235084A (en) | 2007-01-31 | 2007-01-31 | Method for preparing bone morphogenic protein BMP-2 mature peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101235084A true CN101235084A (en) | 2008-08-06 |
Family
ID=39919019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100671383A Pending CN101235084A (en) | 2007-01-31 | 2007-01-31 | Method for preparing bone morphogenic protein BMP-2 mature peptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101235084A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101831432A (en) * | 2010-04-19 | 2010-09-15 | 浙江理工大学 | Biosynthesis method and application of bone morphogenetic protein-2 |
| CN103623417A (en) * | 2013-12-18 | 2014-03-12 | 东华大学 | Application of functionalized polyamide-amine dendrimer nanocomposite |
| CN111269916A (en) * | 2020-03-17 | 2020-06-12 | 珠海深泓鑫生物科技有限公司 | Human bone morphogenetic protein 2 coding gene suitable for escherichia coli expression |
| CN113603792A (en) * | 2021-08-26 | 2021-11-05 | 深圳市人民医院 | Recombinant bone morphogenetic protein-2 and preparation method and application thereof |
-
2007
- 2007-01-31 CN CNA2007100671383A patent/CN101235084A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101831432A (en) * | 2010-04-19 | 2010-09-15 | 浙江理工大学 | Biosynthesis method and application of bone morphogenetic protein-2 |
| CN101831432B (en) * | 2010-04-19 | 2012-10-03 | 浙江理工大学 | Biosynthesis method and application of bone morphogenetic protein-2 |
| CN103623417A (en) * | 2013-12-18 | 2014-03-12 | 东华大学 | Application of functionalized polyamide-amine dendrimer nanocomposite |
| CN103623417B (en) * | 2013-12-18 | 2016-01-20 | 东华大学 | A kind of application of nano-complex of functionalization Polyamidoamine Dendrimers |
| CN111269916A (en) * | 2020-03-17 | 2020-06-12 | 珠海深泓鑫生物科技有限公司 | Human bone morphogenetic protein 2 coding gene suitable for escherichia coli expression |
| CN111269916B (en) * | 2020-03-17 | 2023-06-13 | 珠海深泓鑫生物科技有限公司 | Human bone morphogenetic protein 2 coding gene suitable for escherichia coli expression |
| CN113603792A (en) * | 2021-08-26 | 2021-11-05 | 深圳市人民医院 | Recombinant bone morphogenetic protein-2 and preparation method and application thereof |
| CN113603792B (en) * | 2021-08-26 | 2023-06-30 | 深圳市人民医院 | Recombinant bone morphogenetic protein-2 and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113717290B (en) | Composite transdermal recombinant fibronectin and application thereof | |
| Efimov et al. | The thrombospondin-like chains of cartilage oligomeric matrix protein are assembled by a five-stranded α-helical bundle between residues 20 and 83 | |
| US5962267A (en) | Proinsulin derivative and process for producing human insulin | |
| CN107245494A (en) | Efficient soluble expression and purification method of Abeta 42 in escherichia coli | |
| CN111454350B (en) | Recombinant fibronectin mutant and application thereof | |
| CN110845603A (en) | Human collagen 17-type polypeptide, production method and use thereof | |
| KR100959549B1 (en) | A Method of Producing Glucagon-like Peptide 1 GLP-17-36 And An GLP-1 Analogue | |
| Liew et al. | Preparation of recombinant thioredoxin fused N-terminal proCNP: analysis of enterokinase cleavage products reveals new enterokinase cleavage sites | |
| CN102839182B (en) | Method for preparing recombinant human nerve growth factor by using Escherichia coli expression system | |
| CN101418290A (en) | High efficiency ELP fusion protease as well as preparation and application thereof | |
| CN110724187B (en) | Recombinant engineering bacterium for efficiently expressing liraglutide precursor and application thereof | |
| WO2013020064A1 (en) | Collagen 7 and related methods | |
| CN109402134A (en) | A kind of preparation method and applications of the engineering bacteria of high efficient expression growth hormone | |
| CN101235084A (en) | Method for preparing bone morphogenic protein BMP-2 mature peptide | |
| US12071459B2 (en) | Amino acid sequence of recombinant human bone morphogenetic protein-2 | |
| CN112500495A (en) | Purification method and application of ELP-III type collagen | |
| RU2354702C2 (en) | RECOMBINANT PLASMID DNA pHINS11 CODING HYBRID PROTEIN-HUMAN INSULIN PRECURSOR, Escherichia coli CELL, TRANSFORMED WITH RECOMBINANT PLASMID DNA pHINS11, Escherichia coli BACTERIA STRAIN JM109/pHINS11 - PRODUCER OF HYBRID PROTEIN-HUMAN INSULIN PRECURSOR, AND METHOD OF OBTAINING HUMAN INSULIN | |
| CN108998458B (en) | Process for preparing recombinant human insulin | |
| AU7024098A (en) | Method for cleavage of fusion proteins | |
| CN107176996B (en) | Nucleic acid and recombinant plasmid, preparation method and application thereof | |
| Hwang et al. | A simple method for the purification of an antimicrobial peptide in recombinant Escherichia coli | |
| CN118146352A (en) | Collagen peptide, preparation method and application thereof | |
| JPH08503376A (en) | Prevention of endogenous aminopeptidase-mediated N-terminal amino acid cleavage during expression of heterologous genes in bacteria | |
| CN114380903B (en) | Insulin or analogue precursor thereof | |
| CN112105635A (en) | Leader sequences for higher expression of recombinant proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080806 |